Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 15/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.47 |
| ▸ | HTR3B | O95264 | 5/20 | 0.47 |
| ▸ | HTR3A | P46098 | 5/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486599 | 1.00 | CHRNA7 (0.53) | CHRNA7HPGDHTR3EHTR3BHTR3A | |
| SCHEMBL6497361 | 0.89 | CHRNA7 (0.67) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6497357 | 0.89 | CHRNA7 (0.67) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6487166 | 0.88 | CHRNA7 (0.52) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6487172 | 0.88 | CHRNA7 (0.52) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6487883 | 0.87 | CHRNA7 (0.51) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6487208 | 0.87 | CHRNA7 (0.51) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6487888 | 0.87 | CHRNA7 (0.51) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6487203 | 0.87 | CHRNA7 (0.51) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6498857 | 0.87 | CHRNA7 (0.69) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | claimed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | claimed |
| US-6919359-B2 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PFIZER INC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | CHRNA7 1097/4885HPGD 706/4885HTR3E 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.